The lowered 2026 guidance and the United American underwriting loss are the key negatives, but the 2027 outlook implies confidence in normalization. Watch the Q4 call for updates on Evry's scaling trajectory and CMS claims processing resolution.
Price Chart
Executive Summary
Globe Life reported Q3 2026 net operating income of $4.84 per share, slightly above the year-ago $4.81 but below the $4.89 consensus, while total premium revenue grew 7% YoY to $1.31B. The company lowered full-year 2026 EPS guidance to $15.35-$15.65 from prior $15.40-$15.90, citing high-severity claims at Evry and a CMS claims processing delay, but initiated 2027 guidance of $16.10-$17.10, implying 7.1% midpoint growth.
Key Financial Metrics
Key Facts
- Q3 2026 net operating income of $4.84 per share vs $4.81 year-ago and $4.89 consensus
- Q3 2026 GAAP net income of $4.62 per share vs $4.73 year-ago
- Total premium revenue grew 7% YoY to $1.31B
- Full-year 2026 EPS guidance lowered to $15.35-$15.65 from $15.40-$15.90
- 2027 net operating income guidance initiated at $16.10-$17.10 per share
- Share repurchase guidance raised to $725M-$775M from $670M-$700M
- 1.1 million shares repurchased in Q3 at $185M total cost
- United American health underwriting margin swung to a loss of $6.4M from a gain of $16.1M year-ago, driven by ~$16M Evry loss and ~$7M CMS claims delay
- Life underwriting margin declined 5% YoY to $458M, impacted by annual reserve assumption updates
Financial Impact
2026 EPS guidance lowered by $0.15 at the midpoint; Q3 net operating income missed consensus by $0.05 per share
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Life insurance | $864.6M | +2.4% |
| Health insurance | $446.9M | +15.6% |
Risk Factors
- United American health underwriting loss from Evry group health business and CMS claims delay may persist
- Life underwriting margin decline driven by annual reserve assumption updates could recur
- Share repurchase acceleration may signal lack of better capital deployment opportunities
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000320335-26-000224 |
| Document: gl-20261021.htm | 0000320335-26-000224 |
| Document: 0000320335-26-000224-index-headers.html | 0000320335-26-000224 |
| Document: 0000320335-26-000224-index.html | 0000320335-26-000224 |
| Document: 0000320335-26-000224.txt | 0000320335-26-000224 |
| 8-K Data (Synthetic) | 0000320335-26-000224 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 144 | $157.86 | awaiting T+1 | — | $156.82 (−0.66%) |
Oct 21, 2026 5d ago | 8-K | $168.41 $154.79 | ▲ +8.09% | ▲ +7.57% | $156.82 (+6.88%) |
Oct 21, 2026 5d ago | Press Release | $168.41 $154.79 | ▲ +8.09% | ▲ +7.57% | $156.82 (+6.88%) |
Oct 19, 2026 7d ago | Press Release | $167.85 | awaiting T+1 | — | $156.82 (−6.57%) |
Aug 10, 2026 11w ago | Insider Cluster | $181.04 $177.91 | ▼ −1.73% | ▼ −1.98% | $156.82 (−13.38%) |
Aug 3, 2026 12w ago | Insider Cluster | $183.90 $183.86 | ▲ +0.02% | ▼ −0.18% | $156.82 (+14.73%) |
Jul 30, 2026 12w ago | Insider Cluster | $182.25 $183.64 | ▲ +0.76% | ▼ −0.65% | $156.82 (−13.95%) |
Jul 30, 2026 12w ago | Insider Cluster | $182.25 $183.64 | ▲ +0.76% | ▼ −0.65% | $156.82 (−13.95%) |
Jul 22, 2026 13w ago | Press Release | $171.08 $173.48 | ▲ +1.40% | ▲ +1.30% | $156.82 (−8.34%) |
Jul 8, 2026 15w ago | Press Release | $178.86 $178.98 | ▲ +0.07% | ▼ −0.35% | $156.82 (−12.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers